Physician profile
Garrison S Bennett
NPI 1114990009
$11,771.69
in general payments reported to CMS, 2019-2025
59 companies · $1,656 in 2025
The $1,656 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $1,201 · 2021: $1,920 · 2022: $1,531 · 2023: $2,048 · 2024: $2,157 · 2025: $1,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,842 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,841.92 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,881.68 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,292.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $839.26 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $833.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $762.52 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $643.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.70 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $456.52 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $415.62 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $281.97 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $276.65 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $264.65 | 2019-2021 | |
| Allergan, INC. | $258.96 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $234.39 | 2021 | |
| Corium, LLC | $209.98 | 2023-2024 | Azstarys, Adlarity |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrison Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.